AstraZeneca Inks $2 Billion Deal with Summit Therapeutics

Morning Briefing

• Novo Nordisk has expanded its obesity pipeline through a strategic acquisition in China. The Danish pharmaceutical giant has secured the global rights (excluding China) to a once-weekly, oral GLP-1/GIP receptor agonist from Hengrui Pharma. The deal includes a $300 million upfront payment, with the total potential value reaching $2.6 billion upon the achievement of clinical and regulatory milestones. The candidate is currently entering Phase 1 development.
• Invivyd reported that its experimental monoclonal antibody met its primary clinical trial objectives, demonstrating a safety and tolerability profile superior to currently approved mRNA-based COVID-19 vaccines.
• Immix Biopharma announced breakthrough results for its experimental CAR-T therapy, which induced complete remission in 89% of patients suffering from AL Amyloidosis, a rare autoimmune condition characterized by toxic protein accumulation in vital organs such as the kidneys and heart.

Diminishing Returns Observed in UniQure’s Huntington’s Gene Therapy Four Years Post-Treatment

Data regarding UniQure’s experimental gene therapy, AMT-130, suggests that while the treatment continues to slow the progression of Huntington’s disease four years after administration, the rate of clinical benefit has slowed compared to the previous year. This reduction in efficacy magnitude may present challenges during the upcoming regulatory review process, according to STAT’s Adam Feuerstein.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

To read the rest of this story subscribe to STAT+.

Subscribe

Source link